Search for drugs:
Typing the drug name to query
ZONISAMIDE
DIR Classification
Classification:Less-DIR concern
Severity Score:1
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- ADVERSE REACTIONS
- Post-Marketing Experience
- The following serious adverse events have been reported since approval and use of zonisamide worldwide. These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure.
- Acute pancreatitis, rhabdomyolysis, creatine phosphokinase increased.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
Rhabdomyolysis
34
42878
Other ADRs
3523
14113756
Odds Ratio = 3.177
Drug Property Information
ATC Code(s):
- N03AX15 - zonisamide
- N03AX - Other antiepileptics
- N03A - ANTIEPILEPTICS
- N03 - ANTIEPILEPTICS
- N - NERVOUS SYSTEM
Active Ingredient:zonisamide
Active Ingredient UNII:459384H98V
Drugbank ID:DB00909
PubChem Compound:5734
CAS Number:68291-97-4
Dosage Form(s):capsule
Route(s) Of Administrator:oral
Daily Dose:
- 200.0 mg/day N03AX15
Chemical Structure: 
SMILE Code:
C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
Reference
COHORT STUDY:
N/AOTHER REFERENCE(S):
N/ADisclaimer:
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.